Related Experiment Video
Updated: Aug 5, 2026

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids
Published on: April 25, 2016
Antenatal Corticosteroids: Short-Term Gains, Long-Term Questions-A Meta-Analysis
Marharyta Sobczak1, Barbara Wencka2, Rafał Pawliczak1
1Department of Immunopathology, Division of Biomedical Science, Faculty of Medicine, Medical University of Lodz, 90-752 Lodz, Poland.
Insights
Antenatal corticosteroids (ACSs) reduce newborn mortality but may increase risks for neurodevelopmental disorders. This meta-analysis found increased risks for neurocognitive, hearing, autism, and mental/behavioral disorders following prenatal ACS exposure.
Area of Science:
- Obstetrics and Gynecology
- Neonatal Medicine
- Developmental Pediatrics
Background:
- Antenatal corticosteroids (ACSs) are crucial for preterm birth management, reducing neonatal mortality and morbidity.
- Concerns exist regarding potential long-term adverse effects of fetal exposure to ACSs.
- This meta-analysis evaluates the association between prenatal corticosteroid exposure and long-term health outcomes.
Purpose of the Study:
- To synthesize evidence on the long-term neurological and other outcomes following prenatal exposure to corticosteroids.
- To quantify the risk of specific developmental disorders associated with ACS exposure.
Main Methods:
- Comprehensive literature search of PubMed, Web of Science, and Cochrane Register up to January 2026.
- Inclusion of randomized controlled trials and observational studies reporting long-term outcomes.
- Meta-analysis using a random effects model to calculate pooled effect sizes.
Main Results:
- Increased risk observed for suspected neurocognitive disorder (RR=1.17), hearing impairment (RR=1.18), autism spectrum disorders (RR=1.25), and any mental/behavioral disorder (RR=1.25).
- A slight increase in visual impairment risk was noted (RR=1.03).
- No statistically significant associations were found for other neurological disorders or outcomes.
Conclusions:
- Prenatal corticosteroid exposure may be linked to an elevated risk of specific long-term neurological issues.
- Findings necessitate cautious interpretation due to established neonatal benefits.
- Further long-term observational studies are required to fully assess the benefit-risk profile of ACSs.
Abstract:
Background/Objectives: Antenatal corticosteroids (ACSs) form the basis of prenatal care for women at risk of preterm birth, primarily due to their proven benefits in reducing neonatal mortality and short-term morbidity. However, there are growing concerns about the potential long-term consequences of fetal exposure to ACSs. The aim of the meta-analysis was to assess the relationship between exposure to corticosteroids administered during the prenatal period and long-term effects. Methods: PubMed, Web of Science, and the Cochrane Central Register of Controlled Trials were searched for studies published up to 28 January 2026. Randomized controlled trials and observational studies reporting long-term outcomes after exposure to ACSs were included. A random effects model was used to calculate effect sizes. Results: Among the neurological disorders analyzed, our meta-analysis showed an increased risk of 17% of suspected neurocognitive disorder (RR = 1.17; 95% CI [1.13; 1.21]; p < 0.0001, I2 = 10%), 18% of hearing impairment (RR = 1.18; 95% CI [1.13; 1.24]; p < 0.0001, I2 = 41%), 3% of visual impairment (RR = 1.03; 95% CI [1.01; 1.05]; p = 0.0012, I2 = 0%), 25% of autism spectrum disorders (RR = 1.25; 95% CI [1.09; 1.42]; p = 0.001, I2 = 43%) and 25% of any mental or behavioral disorder (RR = 1.25; 95% CI [1.1; 1.43]; p = 0.0008, I2 = 77%). The results of other neurological disorders, as well as other analyzed outcomes, were not statistically significant (p > 0.05). Conclusions: Although this meta-analysis suggests an increased risk of certain long-term neurological outcomes following prenatal exposure to corticosteroids, these findings should be interpreted with caution in light of the well-documented short-term benefits for newborns and the need for a careful assessment of the benefit-risk ratio and further long-term observational studies.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Cushing Syndrome II: Pathophysiology
Cushing Syndrome I: Introduction